Induction of an antitumoral immune response by wild-type adeno-associated virus type 2 in an in vivo model of pancreatic carcinoma

Pancreas

Volumn 35, Issue 1, 2007, Pages 63-72

  Eisold, Sven ^a   Schmidt, Jan ^b   Ryschich, Eduard ^b   Gock, Michael ^a   Klar, Ernst ^a   Von Knebel Doeberitz, Magnus ^b   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

AAV 2; Immune response; Pancreatic cancer; Parvovirus; Tumor model

Indexed keywords

ADENO ASSOCIATED VIRUS VACCINE; CANCER VACCINE; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS TYPE 2; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MACROPHAGE MIGRATION; MALE; MONOCYTE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL COUNT; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; WILD TYPE;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; CYTOKINES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MONOCYTES; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RATS; RATS, INBRED LEW; TUMOR CELLS, CULTURED;

EID: 34250758650     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e31804b4941     Document Type: Article

References (35)

1. Beger HG, Rau B, Gansauge F, et al. Treatment of pancreatic cancer: challenge of the facts. World J Surg. 2003;27:1075-1084.
2. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother. 1997;20:165-177.
3. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther. 1994;64:529-564.
4. Peyromaure M, Zerbib M. Review of the value of BCG maintenance therapy in superficial bladder tumours. Prog Urol. 2004;14:105-108.
5. Thorne SH, Kirn DH. Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus. Expert Opin Biol Ther. 2004;4:1307-1321.
6. Moehler MH, Zeidler M, Wilsberg V, et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther. 2005;16:996-1005.
7. Tijssen P, Verbeek AJ, Dea S. Evidence of close relatedness between turkey and bovine coronaviruses. Adv Exp Med Biol. 1990;276:457-460.
8. Wetzel K, Menten P, Opdenakker G, et al. Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. J Gene Med. 2001;3:326-337.
9. Giese NA, Raykov Z, DeMartino L, et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther. 2002;9:432-442.
10. Schlehofer JR. The tumor suppressive properties of adeno-associated viruses. Mutat Res. 1994;305:303-313.
11. Eisold S, Dihlmann S, Linnebacher M, et al. Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. Int J Cancer. 2002;100:606-614.
12. Pettengill OS, Faris RA, Bell RH, et al. Derivation of ductlike cell lines from a transplantable acinar cell carcinoma of the rat pancreas. Am J Pathol. 1993;143:292-303.
13. Reidel MA, Ryschich E, Linnebacher M, et al. Effect of interferon alpha/gamma and radiation on human leukocyte antigenes and on cell adhesion molecules in pancreatic cancer. Pancreatology. 2002;2:217-361. Abstract 130.
14. Botquin V, Cid-Arregui A, Schlehofer JR. Adeno-associated virus type 2 interferes with early development of mouse embryos. J Gen Virol. 1994;75:2655-2662.
15. Heilbronn R, Burkle A, Stephan S, et al. The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J Virol. 1990;64:3008-3012.
16. Klein-Bauernschmitt P, von Knebel Doeberitz M, Ehrbar M, et al. Improved efficacy of chemotherapy by parvovirus-mediated sensitisation of human tumour cells. Eur J Cancer. 1996;32:1774-1780.
17. Han L, Parmley TH, Keith S, et al. High prevalence of adeno-associated virus (AAV) type 2 rep DNA in cervical materials: AAV may be sexually transmitted. Virus Genes. 1996;12:47-52.
18. Raykov Z, Savelyeva L, Balboni G, et al. B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression. J Virol. 2005;79:3517-3524.
19. Wistuba A, Weger S, Kern A, et al. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J Virol. 1995;69:5311-5319.
20. Malerba M, Daeffler L, Rommelaere J, et al. Replicating parvoviruses that target colon cancer cells. J Virol. 2003;77:6683-6691.
21. Emens LA, Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer Biol Ther. 2003;2:161-168.
22. Kaufmann A, Salentin R, Meyer RG, et al. Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology. 2001;204:603-613.
23. Garbi N, Arnold B, Gordon S, et al. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004;172:5861-5869.
24. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879-885.
25. Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A. 2004;101:15172-15177.
26. Carlos TM. Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukoc Biol. 2001;70:171-184.
27. Linton MF, Fazio S. Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord. 2003;27:35-40.
28. Hokeness KL, Kuziel WA, Biron CA, et al. Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J Immunol. 2005;174:1549-1556.
29. Kawakami K. Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans. Jpn J Infect Dis. 2004;57:137-145.
30. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy - review of a new approach. Pharmacol Rev. 2003;55:241-269.
31. Erles K, Rohde V, Thaele M, et al. DNA of adeno-associated virus (AAV) in testicular tissue and in abnormal semen samples. Hum Reprod. 2001;16:2333-2337.
32. Mayor HD, Drake S, Stahmann J, et al. Antibodies to adeno-associated satellite virus and herpes simplex in sera from cancer patients and normal adults. Am J Obstet Gynecol. 1976;126:100-104.
33. Tobiasch E, Rabreau M, Geletneky K, et al. Detection of adeno-associated virus DNA in human genital tissue and in material from spontaneous abortion. J Med Virol. 1994;44:215-222.
34. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 1999;59:406-411.
35. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7:131-137.